SCHEMBL16562272

SCHEMBL16562272

COc1ccc(CCNC(=O)C(=O)N2CCOCC2)cc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FKBP1A P62942 2/20 0.63
▸ KDM4E B2RXH2 1/20 0.61
▸ ALDH1A1 P00352 2/20 0.56
▸ SMN1; SMN2 Q16637 4/20 0.55
▸ MEN1 O00255 1/20 0.53
▸ KMT2A Q03164 1/20 0.53
▸ HPGD P15428 2/20 0.52
▸ MAPT P10636 2/20 0.52
▸ POLB P06746 1/20 0.52
▸ GAA P10253 1/20 0.52
▸ APOBEC3G Q9HC16 1/20 0.52
▸ BLM P54132 1/20 0.52
▸ PLAAT3 P53816 1/20 0.52
▸ PLAAT5 Q96KN8 1/20 0.52
▸ PLAAT2 Q9NWW9 1/20 0.52
▸ PLAAT4 Q9UL19 1/20 0.52
▸ HTT P42858 1/20 0.52
▸ RAB9A P51151 1/20 0.52
▸ L3MBTL1 Q9Y468 1/20 0.52
▸ THRB P10828 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16562220 0.88 ALDH1A1 (0.70) ALDH1A1SMN1; SMN2KMT2AMAPTPOLB
SCHEMBL16562105 0.87 ALDH1A1 (0.72) ALDH1A1SMN1; SMN2KMT2AMAPTPOLB
SCHEMBL16562149 0.86 MAPT (0.58) ALDH1A1SMN1; SMN2KMT2AMAPTPLAAT3
SCHEMBL16562188 0.80 NAMPT (0.63) SMN1; SMN2GAAPLAAT3PLAAT5PLAAT2
SCHEMBL17117398 0.80 FKBP1A (0.63) FKBP1AKDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL17919369 0.79 SMN1; SMN2 (0.77) KDM4EALDH1A1SMN1; SMN2KMT2AMAPT
SCHEMBL16562143 0.78 NAMPT (0.58) ALDH1A1SMN1; SMN2MEN1KMT2AHPGD
SCHEMBL16562152 0.78 KDM4E (0.64) FKBP1AKDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL17505994 0.77 SMN1; SMN2 (0.47) FKBP1AALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL17505992 0.77 SMN1; SMN2 (0.47) FKBP1AALDH1A1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9789096-B2 Methods and compositions for selective and targeted cancer therapy BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2017-10-17 — — US disclosed
US-9789096-B2 Methods and compositions for selective and targeted cancer therapy BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2017-10-17 — — US disclosed
US-20160200695-A1 Methods and Compositions for Selective and Targeted Cancer Therapy BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2016-07-14 — — US disclosed
US-20160200695-A1 Methods and Compositions for Selective and Targeted Cancer Therapy BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2016-07-14 — — US disclosed
WO-2015035051-A1 METHODS AND COMPOSITIONS FOR SELECTIVE AND TARGETED CANCER THERAPY BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2015-03-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160200695-A1 Methods and Compositions for Selective and Targeted Cancer Therapy NCOA4, SREBF1, ACOX1 FKBP1A 1322/4885KDM4E 526/4885ALDH1A1 88/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback